• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lyell Immunopharma, Inc. - Common Stock (NQ: LYEL )

    0.6497 +0.0368 (+6.00%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Lyell Immunopharma, Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts
    Via Benzinga
    Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Completes Acquisition of ImmPACT Bio
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
    Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities. 
    Via Benzinga
    Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma Announces Participation in September Investor Conferences
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    LYEL Stock Earnings: Lyell Immunopharma Beats EPS for Q2 2024
    LYEL stock results show that Lyell Immunopharma beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    3 Biotech Stocks to Sell in August Before They Crash & Burn
    Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains. 
    Via InvestorPlace
    Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial
    Lyell Immunopharma shares fell following the release of initial clinical data from its Phase 1 trial of LYL797, a reprogrammed CAR T-cell product. The company reported some severe cases reported in... 
    Via Benzinga
    Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Lyell Immunopharma to Participate in BofA Securities Health Care Conference
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    LYEL Stock Earnings: Lyell Immunopharma Beats EPS for Q1 2024
    LYEL stock results show that Lyell Immunopharma beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    Live Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Tuesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings. 
    Via Benzinga
    Argan Reports Upbeat Earnings, Joins Coupang And Other Big Stocks Moving Higher On Friday
    U.S. stocks were lower, with the Dow Jones index falling over 250 points on Friday. Shares of Argan, Inc. (NYSE: AGX) rose sharply during Friday’s session as the company reported better-than-expected... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Friday is here and we're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers this morning! 
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
    U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) rose sharply during Tuesday’s session. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free 
    Via Benzinga
    Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
    From Lyell Immunopharma, Inc
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.